Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

cers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Sonus, including their respective security holdings, is set forth in Sonus' Amendment # 1 to Form 10-K for the fiscal year ended December 31, 2007, filed with the Securities and Exchange Commission on April 29, 2008, and the Proxy Statement filed with the SEC on July 3, 2008. As of June 30, 2008, OncoGenex' directors and executive officers beneficially owned approximately 1,755,000 shares, or 14.5%, of OncoGenex' capital stock. Investors may obtain additional information regarding the interests of OncoGenex, Sonus and their respective executive officers and directors in the merger by reading the Proxy Statement for such proposed transaction.

The Proxy Statement and other relevant materials, and any other documents filed by Sonus with the SEC, may be obtained free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Sonus by directing a request to: Sonus Pharmaceuticals, Inc., 1522 217th Place SE, Suite 100, Bothell, WA 98021, Phone (425) 686-1500, Fax (425) 686-1600, Attention: Investor Relations.

CONTACT: OncoGenex Media and Investor Contact: Jason I. Spark, Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com


'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Pharma Packaging Solutions announced ... for their 89th year in business. Adding ... Packaging Solutions is preparing packaging operations changes ... new procedures. Establishing training and system validation ... Pharma Packaging Solutions will be ready to ...
(Date:9/16/2014)... NEW ORLEANS , Sept. 16, 2014 ... Austin, Texas -based cybersecurity company focused on ... 2FA ONE, will support the ability to generate a ... As a pioneer of user-based RFID authentication, ... used for physical access, for many years. RFID authentication ...
(Date:9/15/2014)... , Sept. 15, 2014   Global ... innovator of scientific products and services for satellite ... Acquisition Solution for Integrated Services (OASIS) from the ... GST was selected to provide the government best-value ... Small Business (SB) category in Pool 4. The ...
(Date:9/15/2014)... go downhill fast when a patient has sepsis, a ... a patient,s blood -- often too fast for antibiotics ... spleen and developed by a team at Harvard,s Wyss ... way doctors treat sepsis. , "Even with the ... care units at least 30 percent of the time," ...
Breaking Biology Technology:Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 22FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4
... (OTC Bulletin Board: MNCN), an innovative, global wellness solutions company, ... the OTC Bulletin Board under the symbol "MNCN." The Company,s ... , "The move to the OTC Bulletin Board will ... investors and help improve our trading liquidity," said Patrick Sheridan, ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced today that it has received a European ... technology for the improved oral delivery of drugs. ... Reverse Micelle Compositions and Uses Thereof" covers lipid ...
... July 8 iZumi Bio, Inc. and Pierian, Inc. ... company, iPierian, Inc. Building on the iZumi infrastructure and ... cellular reprogramming to change the paradigm of drug discovery. ... development of new therapeutics using induced pluripotent stem (iPS) ...
Cached Biology Technology:DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 2DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 3DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 2iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 3iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 4iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 6
(Date:9/16/2014)... XL pipeline (KXL) would likely increase oil sands extraction, ... by the non-profit organization Near Zero. The results are ... and includes both supporters and opponents of the pipeline. ... could lead to significantly higher greenhouse gas emissions, with ... , "This report examines three main scenarios discussed ...
(Date:9/16/2014)... DURHAM, N.H. From the salmon-rich waters of Southeast ... Coast to Downeast Maine,s lobster, lumber and tourist towns, ... their views about coastal environments divide along political lines. ... University of New Hampshire sociologists published this month in ... "We found a lot of environment-related differences from place ...
(Date:9/16/2014)... 2014  Valencell, Inc., a leader in performance biometric ... 18 "Showcase Companies" representing North Carolina,s ... Tech Venture Conference on September 16-17 th at ... Raleigh, North Carolina . Valencell,s President ... during the "Digital Health Spotlight Sector" on how the ...
Breaking Biology News(10 mins):Keystone XL would likely raise oil sands production and greenhouse gas emissions 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... researchers will embark on an unconventional approach to DNA research ... for the ideas to explore scientific frontiers. Chemist Patrick ... were the youngest researchers chosen among several hundred applicants. They ... a senior scientist, growth biology Prof. Rod Hill. The ...
... A long-term field and DNA study by the ... University of Miami, Field Museum of Chicago and others ... Bimini islands, Bahamas, tend to stay near their coastal ... typically focuses on baby sharks confined to shallow habitats, ...
... produced more cheaply using nanoparticle "inks" that allow them ... sides of buildings or rooftops to absorb electricity-producing sunlight. ... chemical engineer, is hoping to cut costs to one-tenth ... process for solar cells gas-phase deposition in a ...
Cached Biology News:Idaho researchers win grant to explore DNA frontier 2Scientists shed new light on behavior of shark 'tweens' and 'teenagers' 2Scientists shed new light on behavior of shark 'tweens' and 'teenagers' 3Lower-cost solar cells to be printed like newspaper, painted on rooftops 2
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
... hydrophobic barrier pen for immunohistochemistry and in ... frozen or paraffin-embedded tissue sections mounted on ... heat-stable, water-repellent barrier that keeps staining reagents ... of reagents when differentially staining two sections ...
Biology Products: